Related Experiment Video
Updated: Jul 8, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
EGFR and colon cancer: a clinical view
J de Castro-Carpeño1, C Belda-Iniesta, E Casado Sáenz
1Medical Oncology Division, University Hospital La Paz, Madrid, Spain. jcastro.hulp@salud.madrid.org
Abstract:
Signalling pathways that emerge from EGFR activation are critical in colon cancer (CC) biology. Its targeting with specific drugs has opened a new window in the treatment of this disease. In this regard, monoclonal antibodies (mAb) have evidenced a high degree of efficiency opposed to the uselessness of tyrosine-kinase inhibitors. Cetuximab is the mAb that has evidenced most activity in CC. After its initial approval as an irinotecan-resistance reversal agent, cetuximab has demonstrated its efficiency from the first line to heavily pretreated patients. In the first line, its addition may increase response rate to chemotherapy, improving liver metastases resection rate. Another promising approach has been suggested from combination schedules with bevacizumab. Panitumumab has been recently approved for CC. Although there is limited clinical experience, the latest data have confirmed its activity in heavily pretreated patients resulting in a clinical benefit vs. best support care. In spite of the clinical benefits, adverse events and the high sanitary cost derived from these drugs force the selection of patients with the highest probability of benefit. At the moment, when EGFR expression evidenced by immunohistochemistry has no value, skin toxicity and, fundamentally, K-Ras mutations may hint at critical information for confirmatory prospective studies.
Insights
Targeting epidermal growth factor receptor (EGFR) with monoclonal antibodies (mAbs) shows promise in colon cancer treatment. K-Ras mutations are key to identifying patients likely to benefit from these therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) signaling pathways are crucial in colon cancer (CC) pathogenesis.
- Targeting EGFR has revolutionized CC treatment, with monoclonal antibodies (mAbs) demonstrating significant efficacy.
Purpose of the Study:
- To review the efficacy of EGFR-targeting mAbs in colon cancer treatment.
- To discuss the role of K-Ras mutations in patient selection for EGFR-targeted therapies.
Main Methods:
- Review of clinical trial data and scientific literature on EGFR inhibitors in colon cancer.
- Analysis of the effectiveness of monoclonal antibodies like cetuximab and panitumumab.
- Evaluation of predictive biomarkers for treatment response.
Main Results:
- Monoclonal antibodies (mAbs) like cetuximab and panitumumab are effective in various lines of colon cancer treatment, including in heavily pretreated patients.
- Addition of mAbs to chemotherapy may improve response rates and resectability of liver metastases.
- K-Ras mutations, not EGFR expression via immunohistochemistry, are critical indicators for patient selection.
Conclusions:
- EGFR-targeting mAbs represent a significant advancement in colon cancer therapy.
- Patient selection based on K-Ras mutation status is essential for optimizing treatment outcomes and managing costs.
- Further prospective studies are needed to validate predictive biomarkers for EGFR-targeted therapies.
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:21Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal